IMMUNOREACTIVITY OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) IN TRANSITIONAL CELL CARCINOMA OF URINARY BLADDER

ABDUL HASEEB KHAN, SAEED AKHTAR KHAN
NASEER AHMAD CHAUDRHY AND MUHAMMAD TAYYAB
Department of Pathology, Postgraduate Medical Institute, Lahore

To evaluate Proliferating cell nuclear antigen in transitional cell carcinoma. Descriptive. A total of fifty transurethally resected bladder tumour samples (TUR BT) were collected from Mayo Hospital, Lahore and Services Hospital, Lahore and processed for H&E and PCNA stain. The grading of tumours were made on H&E stain. While Proliferating cell nuclear antigen labeling index was recorded for each case. The mean PCNA labeling index was significantly higher in grade III when compared with tumours of grade II. (p<0.001) carcinoma. Similarly mean PCNA labeling index was significantly higher (p<0.05) in patients having duration of symptoms up to 3 month when compared with the patients having longer duration of symptoms. The mean PCNA labeling index had significantly higher value in high grade tumours as compared to low grade tumours (p<0.001). Although determination of PCNA labeling index is costly yet it has significant role in tumour grading.

Malignancies of urinary bladder are one of the leading malignancies in the developed countries. The incidence is also high in Northern Africa and Western Asia. The world wide estimate of carcinoma of urinary bladder of new cases is 261,000 annually. Amongst these, more than 50,000 cases and an estimate of 9500 deaths have been predicted in United States alone. The incidence is three times more in males as compared to females and twice as common in whites as compared to blacks.

Carcinoma of urinary bladder accounts for 2% of all malignant tumors and approximately 7% of all urinary tract malignancies in males. Transitional cell carcinoma constitutes the vast majority of bladder cancers. It is the second most common malignancy in the genitourinary tract.

Carcinoma of urinary bladder is the 8th common malignancy in Pakistan. It is the fourth common malignancy in men and its incidence is 5.4% in North West Pakistan. It has frequency of 5.75% among men and 1.61% among women.

Recently, a series of unique proteins that may serve as useful antigenic markers have been isolated from actively dividing cells, like Ki-67 and proliferating cell nuclear antigen. The proliferating cell nuclear antigen (PCNA), also known as Cyclin, is a nuclear protein of 36 kd whose level of synthesis correlate directly with rate of cellular proliferation and DNA synthesis. Monoclonal antibodies have recently been generated to PCNA/Cyclin. Monoclonal antibodies to PCNA/Cyclin (PC 10) have been shown to label the proliferating cell in vitro as well as in alcohol fixed, paraffin embedded tissue.

The PCNA labeling index in urinary bladder cancer may prove to be new objective and quantitative assay of the biological potential or individual tumour. The new immunohistochemical method using anti-PCNA antibodies (PC 10) to study tumour cell kinetic has overcome many of inherent difficulties of conventional auto radiographic technique as well as Bromodeoxyuridine labeling index.

So anti PCNA monoclonal antibodies have been found to be useful tool and good proliferative marker. PCNA expression has been assessed as prognostic indicator in renal cell carcinoma. Positive correlation between PCNA immunostaining and AgNOR has been observed in histological grading of gastrointestinal stromal tumors.

Similarly a significant difference was observed between grade II and grade III in carcinoma of urinary bladder when two parameters AgNOR and PCNA were used. A directly proportional relationship was also demonstrated between each of PC 10 and AgNOR scores and the clinical stage. So PC 10 and AgNOR scores may be important prognostic indices in carcinoma of urinary bladder.

As PCNA staining have been used successfully for evaluation of different malignancies. This study was carried out to evaluate PCNA Immunoreactivity in different grades of transitional cell carcinoma.

MATERIALS AND METHODS
Fifty sample of Transurethally resected urinary bladder tumour (TUR BT) were collected in 10% formalin solution from Mayo Hospital and Services Hospital Lahore. These formalin fixed tissue
were processed in automatic processor for H&E staining and PCNA staining using the commercially available reagents of DAKO Corporation, USA, according to manufacturer instructions. The grading of tumour was made on H&E stain.

MICROSCOPIC INTERPRETATION
The average labeling index was expressed as percentage ratio of total labelled cells to the total number of cells counted.\textsuperscript{15}

RESULTS
The proliferating cell antigen labeling index in transitional cell carcinoma ranged from 2\% to 39\% with the mean±SD value of 19.12±8.10. Mean PCNA labeling index decreased as the ages of the patients increased. Comparison of mean PCNA labeling index in different age groups is table 1. Mean PCNA labeling index was significantly higher in grade III when compared with tumours of grade (table 2). Similarly mean PCNA labeling index was significantly higher (p<0.05) in patients having duration of symptoms up to 3 month when compared with the patients having longer duration of symptoms (table 3).

DISCUSSION
Carcinoma of urinary bladder accounts for 2\% of all malignant tumours and approximately 7\% of all urinary tract malignancies in males.\textsuperscript{5} It is the second most common malignancy in the genitourinary tract.\textsuperscript{6} Smoking and exposure to a variety of chemical compounds are main known factors promoting the onset of carcinoma of urinary bladder.\textsuperscript{21} Immunostaining of the PCNA provides important information about cell kinetic and is performed on routinely obtained formalin fixed paraffin embedded materials.\textsuperscript{18} PCNA plays an essential role in nucleic acid metabolism in all eukaryotes. The PCNA protein interacts with a large number of proteins. These proteins can be divided into two groups, the first contain proteins that have a known enzymatic activity, the second contain regulatory proteins that are included in cell cycle progression.\textsuperscript{22} The PCNA gene codes for a protein that is necessary for cellular DNA synthesis and cell cycle progression.\textsuperscript{22} The ratio of cyclin/DNA remain constant during S phase.\textsuperscript{23} Normal epithelium has distinct PCNA pattern of expression which is confined to basal cell layer while dysplastic urothelium and carcinoma in situ showed irregularly distributed pattern of PCNA immunoreactive nuclei in all the layers. In tumour cells complexes, the pattern of PCNA immunoreactivity was different in papillary and primary infiltrating transition cell carcinoma.\textsuperscript{24}

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|}
\hline
Age groups (years) & No of cases & Mean PCNA labeling index ± SD \\
\hline
40 – 49 & 5 & 25.80 ± 10.03 \\
50 – 59 & 18 & 19.33 ± 11.06 \\
60 – 69 & 22 & 17.77 ± 9.51 \\
70 – 79 & 5 & 17.60 ± 11.76 \\
Total & 50 & 19.12 ± 8.10 \\
\hline
\end{tabular}
\caption{Mean PCNA labeling index in different age groups.}
\end{table}

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|}
\hline
Grade & No of cases & PCNA labeling index ± SD \\
\hline
II & 34 & 16.61 ± 9.98 \\
III & 16 & 24.43 ± 7.01 \\
\hline
\end{tabular}
\caption{Comparison of Grade of transitional cell carcinoma with mean PCNA labeling index.}
\end{table}

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|}
\hline
Duration of Symptoms (months) & No of cases & PCNA labeling index ± SD \\
\hline
1–3 & 18 & 22.16 ± 12.20 \\
4–12 & 32 & 15.90 ± 11.0 \\
Total & 50 & 19.12 ± 8.10 \\
\hline
\end{tabular}
\caption{Comparison of Mean PCNA labeling index with duration of symptoms.}
\end{table}
IMMUNOREACTIVITY OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA)

The PCNA immunostaining is useful and reproducible method of assessing one aspect of cellular proliferative activity. It has some advantages over flow cytometry in that it maintains tissue integrity and morphologic relationship.25

The percentage of tumour cells with positive staining for PCNA was found to correlate well with histological grading.26 The results have been shown good relation between PCNA and histopathological grade of tumour.27 The fraction of PCNA positive nuclei ranges between 0% to 100%. In WHO grade tumour samples, only occasional cells are positive for PCNA where as nearly all the nuclei are positive in WHO grade 3 tumours. This indicates that the cell proliferation can be assessed by PCNA/Cyclin immunostaining in transitional cell carcinoma.28

In our study, cells of transitional cell carcinoma showed immunoreactivity for PCNA. Only five cases had PCNA labeling index of less than 10% with mean ± SD value of 5.40±3.22% (Fig 1). The rest of cases had mean PCNA labeling index ± SD 22.84±8.97% which was statistically higher (p<0.01) than the above group. These finding are similar to that of Chen et al.29 in which they reported mean PCNA labeling index ± SD, of 12.58±12.33% in superficial tumours and 34.55±21.89% in invasive tumours.

All above studies suggest that proliferating cell nuclear antigen labeling index in carcinoma of urinary bladder may prove to be an objective and quantitative assay of biological aggressiveness and may provide significant prognostic information.

The PCNA labeling index had significantly higher value in high grade tumours as compared to low grade tumours.30-31 Similarly the PCNA labeling index in our study was significantly higher (p<0.001) than the above group. These finding are similar to that of Chen et al.29 in which they reported mean PCNA labeling index ± SD, of 12.58±12.33% in superficial tumours and 34.55±21.89% in invasive tumours.

Similarly the mean PCNA labeling index has shown significant difference ( p<0.05) in tumours having shorter duration of symptoms (1—3 months) as compared to tumours having longer duration of symptoms (table 3).

Finally our studies indicates that PCNA labeling index has significant role in tumour grading and future studies may prove it as reliable parameter in grading of transitional cell carcinoma and thus helpful in follow up of patients of transitional cell carcinoma.

REFERENCES


18. Morisaki Y, Shima S, Yoshizumi Y, Suziura Y, Tana-
ka S, Tamai S. PCNA immunostaining combined
with AgNOR staining in esophageal squamous cell
carcinoma to identify patients with a poor progno-

K. Prognostic value of proliferative activity of ovar-
ian carcinoma as revealed by PCNA and AgNOR

20. Stevens A. The haematoxylins. In:Bancroft JD, Ste-
vens A[eds]. Theory and practice of histological
techniques. 3rd ED. London Churchill Livingstone,
1990; 107-117.

for a role of human papillomaviruses in transitional
carcinoma of the bladder. J urol 1998; 159: 86-
94.

22. Rizzo MG, Ottavio L, Travali S, Chang CD, Kamin-
ska B, Baserga R. The promoter of the human proli-
ferating cell nuclear antigen. (PCNA) gene is bidire-

23. Bruno S, Crissman HA, Bauer KD, Darznkiewicz Z.
Changes in cell nuclei during S phase progressive
chromatin condensation and altered expression of
the proliferation associated nuclear protein ki 67,
cyclin (PCNA) p105 and p34. Exp Cell Res 1991;
196: 99-106.

K, Weyer R et al. Proliferative activitat und expres-
sion des p-protein in udergangszellkarinomen der
harnblase. [Proliferative activity and p 53 expres-
sion in transitional cell carcinoma of urinary

25. Benjamin DR. Proliferative cell nuclear antigen
(PCNA) and pediatric Pathol 1991; 11: 507-509.

26. Yu CC, Hall PA, Hall PA, Fletcher CD, Camplejohn
RS, Waseem NH, Lane DP, Levison DA. Haemang-
ioniopericytoma; the prognostic value of immuno-
histochemical staining with a monoclonal antibod-
ies to proliferating cell nuclear antigen (PCNA).

27. Woods AL, Hall PA, Shephard NA, Hanby AM, Wa-
seem NH, Lane DP, Levison DA. The assessment of
proliferating cell nuclear antigen (PCNA) immuno-
staining in gastrointestinal lymphoma and its rela-
tionship to histological grade. Histopayhology 1991;
19: 235-238.

28. Lipponen PK, Eskelinen MJ. Cell proliferation of
transitional cell bladder cancer determined by PC-
NA/Cylin immunostaining. A Histopathological

29. Chen G, Lin MS, Li RS. Expression and prognostic
value of proliferating cell nuclear antigen in transi-
tional cell carcinoma of urinary bladder. Urol Res

30. Yushikawa H, Ikeuchi H, Onodera Y, Kai Y. [Exp-
ression of PCNA/Cyclin, p53, C-erb B-2 versus histo-
logical grade in transition cell carcinoma of urinary

31. Iizumi T, Liyama T, Tanaka W, Okada E, Kamiyama
Y, Okano Y et al. Immunohistochemical studies of
proliferating cell nuclear antigen and Cathepsin D
in transitional cell carcinoma of the urinary blad-